NCT04387201View on ClinicalTrials.gov

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

October 6, 2023

Study Completion Date

October 6, 2023

Conditions
Glucose IntoleranceOverweight and ObesityDrug EffectAdiposity
Interventions
DRUG

Cyanocobalamin

Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.

DRUG

Dulaglutide

Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center, Houston

OTHER

NCT04387201 - GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response | Biotech Hunter | Biotech Hunter